The safety and efficacy of radium-223 dichloride for the treatment of advanced prostate cancer.
Loading...
Embargo End Date
ICR Authors
Authors
Wilson, JM
Parker, C
Parker, C
Document Type
Journal Article
Date
2016-09-01
Date Accepted
2016-08-05
Abstract
INTRODUCTION: A number of drugs have been shown to extend life expectancy in castration-resistant prostate cancer (CRPC). Skeletal related events (SREs) secondary to bone metastases cause significant morbidity for men with CRPC. The α-emitting radiopharmaceutical radium-223 dichloride has been shown to improve overall survival, time to symptomatic skeletal events (SSEs) and quality of life in CRPC. AREAS COVERED: The development of radium-223 from pre-clinical studies to the evidence of efficacy and safety from a phase 3 trial is discussed as well as its pharmacokinetics and metabolism. The integration of radium-223 into routine care for patients with advanced prostate cancer is included including a comparison with other agents in this setting. Expert commentary: The risk/benefit ratio for radium-223 is very similar to that of other agents used in the CRPC setting and is a treatment option for men unsuitable for cytotoxic chemotherapy because of comorbidities. The ALSYMPCA trial demonstrated an improvement in SSEs with radium-223. This is a clinically relevant end-point as not all radiologically-detected SREs are apparent to patients. The correct sequencing of the life-prolonging treatments available to men with CRPC is subject to debate. Radium-223 therapy should be considered before the development of visceral metastases. Drug-combination studies are underway.
Citation
Expert review of anticancer therapy, 2016, 16 (9), pp. 911 - 918
Source Title
Publisher
TAYLOR & FRANCIS LTD
ISSN
1473-7140
eISSN
1744-8328